Title: Incretin dysfunction and hyperglycemia in cystic fibrosis: Role of acyl-ghrelin.

Authors: Sun, Xingshen; Yi, Yaling; Liang, Bo; Yang, Yu; He, Nan; Ode, Katie Larson; Uc, Aliye; Wang, Kai; Gibson-Corley, Katherine N; Engelhardt, John F; Norris, Andrew W

Published In J Cyst Fibros, (2019 07)

Abstract: Insulin secretion is insufficient in cystic fibrosis (CF), even before diabetes is present, though the mechanisms involved remain unclear. Acyl-ghrelin (AG) can diminish insulin secretion and is elevated in humans with CF.We tested the hypothesis that elevated AG contributes to reduced insulin secretion and hyperglycemia in CF ferrets.Fasting AG was elevated in CF versus non-CF ferrets. Similar to its effects in other species, AG administration in non-CF ferrets acutely reduced insulin, increased growth hormone, and induced hyperglycemia. During oral glucose tolerance testing, non-CF ferrets had responsive insulin, glucagon like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) levels and maintained normal glucose levels, whereas CF ferrets had insufficient responses and became hyperglycemic. Interestingly in wild-type ferrets, the acyl-ghrelin receptor antagonist [D-Lys3]-GHRP-6 impaired glucose tolerance, and abolished insulin, GLP-1, and GIP responses during glucose tolerance testing. By contrast, in CF ferrets [D-Lys3]-GHRP-6 improved glucose tolerance, enhanced the insulin-to-glucose ratio, but did not impact the already low GLP-1 and GIP levels.These results suggest a mechanism by which elevated AG contributes to CF hyperglycemia through inhibition of insulin secretion, an effect magnified by low GLP-1 and GIP. Interventions that lower ghrelin, ghrelin action, and/or raise GLP-1 or GIP might improve glycemia in CF.

PubMed ID: 30738804

MeSH Terms: No MeSH terms associated with this publication